- Merck & Co Inc (NYSE:MRK) is reportedly mulling buying cancer-focused biotech Seagen Inc (NASDAQ:SGEN), Wall Street Journal reported citing people familiar with the matter.
- If the deal happens, it would be significant, given Seagen's market value of roughly $28 billion.
- According to the report, some people said other unnamed suitors are also eying Seagen, a perennially speculated takeover target.
- Also Read: Amid Domestic Violence Allegation, Longtime Seagen CEO Takes Leave of Absence.
- Talks have been underway for a while, the people said.
- Though the people cautioned that pulling off the deal could be tricky given the heightened risk of a regulatory challenge.
- WSJ also mentioned that a marketing agreement is also possible between Merck and Seagen.
- Related: Read Why This Analyst Is 'Encouraged' By Seagen's Q1 Sales.
- Price Action: SGEN shares are up 13.30% at $166.26, and MRK stock is up 0.06% at $84.94 during the market session on the last check Friday.
- Photo via Pixabay
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Merck Shows Takeover Interest In Seagen: WSJ
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks